{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:38:10Z","timestamp":1760834290593,"version":"build-2065373602"},"reference-count":26,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,3,15]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study sought whether higher risk patients with coronary heart disease (CHD) benefit more from intensive disease management.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Longitudinal cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>State-wide public hospitals (Queensland, Australia).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>This longitudinal study included 20\u2009426 patients hospitalised in 2010 with CHD as the principal diagnosis. Patients were followed-up for 5\u2009years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Primary and secondary outcomes and measures<\/jats:title>\n                  <jats:p>The primary outcome was days alive and out of hospital (DAOH) within 5\u2009years of hospital discharge. Secondary outcomes included all-cause readmission and all-cause mortality. A previously developed and validated risk score (PEGASUS-TIMI54) was used to estimate the risk of secondary events. Data on sociodemography, comorbidity, interventions and medications were also collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>High-risk patients (n=6573, risk score \u22656) had fewer DAOH (\u2206=\u2212142 days (95%\u2009CI: \u2212152 to \u2013131)), and were more likely to readmit or die (all p&lt;0.001) than their low-risk counterparts (n=13\u2009367, risk score &lt;6). Compared with patients who were never prescribed a medication, those who consumed maximal dose of betablockers (\u2206=39\u2009days (95%\u2009CI: 11 to 67)), angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers (\u2206=74\u2009days (95%\u2009CI: 49 to 99)) or statins (\u2206=109\u2009days (95%\u2009CI: 90 to 128)) had significantly greater DAOH. Patients who received percutaneous coronary intervention (\u2206=99\u2009days (95%\u2009CI: 81 to 116)) or coronary artery bypass grafting (\u2206=120\u2009days (95%\u2009CI: 92 to 148)) also had significantly greater DAOH than those who did not. The effect sizes of these therapies were significantly greater in high-risk patients, compared with low-risk patients (interaction p&lt;0.001). Analysis of secondary outcomes also found significant interaction between both medical and interventional therapies with readmission and death, implicating greater benefits for high-risk patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CHD patients can be effectively risk-stratified, and use of this information for a risk-guided strategy to prioritise high-risk patients may maximise benefits from additional resources spent on intensive disease management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-057856","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T12:30:55Z","timestamp":1651667455000},"page":"e057856","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Application of a risk-guided strategy to secondary prevention of coronary heart disease: analysis from a state-wide data linkage in Queensland, Australia"],"prefix":"10.1136","volume":"12","author":[{"given":"Quan L","family":"Huynh","sequence":"first","affiliation":[{"name":"Baker Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Son","family":"Nghiem","sequence":"additional","affiliation":[{"name":"Griffith University, Nathan, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Byrnes","sequence":"additional","affiliation":[{"name":"Griffith University, Nathan, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A","family":"Scuffham","sequence":"additional","affiliation":[{"name":"School of Medicine, Griffith University, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9065-0899","authenticated-orcid":false,"given":"Thomas","family":"Marwick","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"2025101813063535000_12.5.e057856.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs092"},{"key":"2025101813063535000_12.5.e057856.2","unstructured":"Australian Bureau of Statistics . Causes of death 2017, ABS cat. no. 3303.0 2018."},{"key":"2025101813063535000_12.5.e057856.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"2025101813063535000_12.5.e057856.4","unstructured":"Marwick TH , Huynh Q , Venkataraman P . No second chances. Baker Heart and Diabetes Institute, 2019."},{"key":"2025101813063535000_12.5.e057856.5","first-page":"1600","article-title":"Cardiovascular efficacy and safety of PCSK9 inhibitors: systematic review and meta-analysis including the odyssey outcomes trial","volume":"34","author":"Turgeon","year":"2018","journal-title":"Can J Cardiol"},{"key":"2025101813063535000_12.5.e057856.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"2025101813063535000_12.5.e057856.7","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.5694\/mja14.01157","article-title":"Adherence to secondary prevention therapies in acute coronary syndrome","volume":"201","author":"Thakkar","year":"2014","journal-title":"Med J Aust"},{"key":"2025101813063535000_12.5.e057856.8","unstructured":"National Institute for Health and Care Excellence . Secondary prevention after a myocardial infarction - Quality Standard (QS99) 2015."},{"key":"2025101813063535000_12.5.e057856.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"2025101813063535000_12.5.e057856.10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15420\/icr.2018.16.2","article-title":"Risk stratification in patients with coronary artery disease: a practical Walkthrough in the landscape of prognostic risk models","volume":"13","author":"Buccheri","year":"2018","journal-title":"Interv Cardiol"},{"key":"2025101813063535000_12.5.e057856.11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.amjcard.2018.04.051","article-title":"Socioeconomic disadvantage and days at home after hospital discharge of patients with heart failure","volume":"122","author":"Huynh","year":"2018","journal-title":"Am J Cardiol"},{"key":"2025101813063535000_12.5.e057856.12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2018.11.142","article-title":"A new score based on the PEGASUS-TIMI 54 criteria for risk stratification of patients with acute myocardial infarction","volume":"278","author":"Cosentino","year":"2019","journal-title":"Int J Cardiol"},{"key":"2025101813063535000_12.5.e057856.13","first-page":"40","article-title":"Estimating effects for non-linearly scaled covariates in regression models Part I - Linear link function models","volume":"11","author":"Hosmer","year":"2004","journal-title":"Australasian Epidemiologist"},{"key":"2025101813063535000_12.5.e057856.14","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176345976"},{"key":"2025101813063535000_12.5.e057856.15","doi-asserted-by":"publisher","DOI":"10.2307\/2670170"},{"key":"2025101813063535000_12.5.e057856.16","unstructured":"Pink B . 2011 census of population and housing: socioeconomic index for areas. Canberra: Australian Bureau of Statistics, 2013. Available: http:\/\/www.ausstats.abs.gov.au\/Ausstats\/subscriber.nsf\/0\/22CEDA8038AF7A0DCA257B3B00116E34\/$File\/2033.0.55.001%20seifa%202011%20technical%20paper.pdf"},{"key":"2025101813063535000_12.5.e057856.17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001046"},{"key":"2025101813063535000_12.5.e057856.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0803563"},{"key":"2025101813063535000_12.5.e057856.19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.amjcard.2017.10.031","article-title":"Validation of predictive score of 30-day hospital readmission or death in patients with heart failure","volume":"121","author":"Huynh","year":"2018","journal-title":"Am J Cardiol"},{"key":"2025101813063535000_12.5.e057856.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.109.883256"},{"key":"2025101813063535000_12.5.e057856.21","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302532"},{"key":"2025101813063535000_12.5.e057856.22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004310"},{"key":"2025101813063535000_12.5.e057856.23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cardfail.2019.01.015","article-title":"Influence of risk on reduction of readmission and death by disease management programs in heart failure","volume":"25","author":"Huynh","year":"2019","journal-title":"J Card Fail"},{"key":"2025101813063535000_12.5.e057856.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.020730"},{"key":"2025101813063535000_12.5.e057856.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.00638.x"},{"key":"2025101813063535000_12.5.e057856.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2015.02.002"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-057856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:06:47Z","timestamp":1760818007000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-057856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,4]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/bmjopen-2021-057856"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-057856","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}